Norway· NO-ID_410484C1-93AB-4715-882A-44E09ECDB0ED
Emblaveo
A aztreonam und beta-lactamase-inhibitor product containing aztreonam + avibactam, registered in Norway by Pfizer Europe MA EEIG. The same ATC class is registered in 7 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Aztreonam und beta-lactamase-inhibitor is registered in 7 of 19 countries.
Countries holding a registration under ATC J01DF51 (aztreonam und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 4 of them publish a price we can compare per daily dose
Aztreonam und beta-lactamase-inhibitor · ATC J01DF51
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
The record
At a glance
FEST (Norway)- Active substance
- Aztreonam + Avibactam
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Norway (NO)
- ATC code
- J01DF51
- ATC class
- Aztreonam und Beta-Lactamase-Inhibitor
- Defined daily dose
- 6 g, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- October 2, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_410484C1-93AB-4715-882A-44E09ECDB0ED
- no_varenummer07746810NOK 29735.6
- gtin5415062122150
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aztreonam und beta-lactamase-inhibitor in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEMBLAVEOAbbVie Inc.
- SpainEMBLAVEO 1,5 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPfizer Europe Ma Eeig
- FinlandEmblaveoPfizer Europe MA EEIG
- FranceEMBLAVEO 1,5 g/0,5 g, poudre pour solution à diluer pour perfusionPFIZER EUROPE MA EEIG (BELGIQUE)
- United KingdomEmblaveo 1.5g/0.5g powder for concentrate for solution for infusion vialsPfizer Ltd
- CzechiaEMBLAVEOPfizer Europe MA EEIG, Bruxelles
- NetherlandsEmblaveo 1,5 g/0,5 g poeder voor concentraat voor oplossing voor infusiePfizer Europe MA EEIG
- PolandEmblaveoPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Emblaveo
- Liechtenstein · Emblaveo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d8104011-ba49-487d-8779-c4ab04c0be7f GET /v1/drugs/d8104011-ba49-487d-8779-c4ab04c0be7f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Aztreonam og betalaktamasehemmer",
"merkevare_id": "ID_410484C1-93AB-4715-882A-44E09ECDB0ED",
"name_form_strength": "Emblaveo pulv til kons til inf væske, oppl 1,5 g/0,5 g",
"prescription_group": "C"
}See everything about aztreonam und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.